Day: May 15, 2024

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Written by Customer Service on . Posted in Public Companies.

ELI-002 2P Phase 1 preliminary data published in Nature Medicine ELI-002 2P Phase 1 data characterizing the CD4 and CD8 profile of the KRAS immune response and ELI-002-generated antigen spreading presented at the AACR Annual Meeting ELI-002 7P Phase 1 preliminary data to be presented at the ASCO Annual Meeting (“ASCO”) in June 2024 ELI-002 7P randomized Phase 2 trial enrollment expected to complete in fourth quarter 2024 BOSTON, May 15, 2024 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided recent corporate and clinical updates. “During the first quarter, we continued to make great...

Continue reading

DallasNews Corporation Announces First Quarter 2024 Financial Results

Written by Customer Service on . Posted in Public Companies.

DALLAS, May 15, 2024 (GLOBE NEWSWIRE) — DallasNews Corporation (Nasdaq: DALN) (the “Company”) today reported a first quarter 2024 net loss of $1.4 million, or $(0.25) per share, and an operating loss of $1.8 million. In the first quarter of 2023, the Company reported a net loss of $2.6 million, or $(0.49) per share, and an operating loss of $2.8 million. For the first quarter of 2024, on a non-GAAP basis, DallasNews reported an operating loss adjusted for certain items (“adjusted operating loss”) of $0.8 million, an improvement of $1.4 million or 64.0 percent when compared to an adjusted operating loss of $2.2 million reported in the first quarter of 2023. The improvement is primarily due to expense savings of $2.5 million in distribution, $1.6 million in employee compensation and benefits, and $0.9 million in newsprint, partially...

Continue reading

Alstom SA: 2023/24 Universal Registration Document available

Written by Customer Service on . Posted in Public Companies.

15 May 2024 – Alstom’s 2023/24 Universal Registration Document, which includes notably the Annual Financial Report, was filed with the “Autorité des marchés financiers” (AMF) on 15 May 2024. This document is available to the public free of charge in accordance with applicable regulation and may be viewed on Alstom’s website (https://www.alstom.com/finance), as well as on the AMF website (www.amf-france.org). The following information is included in the 2023/24 Universal Registration Document: •the Annual Financial Report, including notably the consolidated financial statements, the statutory accounts, the related Statutory Auditors’ reports and the management report, •the Board of Directors’ report on corporate governance, •the Statutory Auditors’ special report on related-party agreements and...

Continue reading

Uniti Group Inc. to Participate at the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference

Written by Customer Service on . Posted in Public Companies.

LITTLE ROCK, Ark., May 15, 2024 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its President and Chief Executive Officer, Kenny Gunderman, and Vice President, Investor Relations & Treasury, Bill DiTullio, are scheduled to participate at the J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference on May 22, 2024 in Boston, MA. Any investor materials will be made available on Uniti’s Investor Relations website at investor.uniti.com under the Events & Presentations tab. ABOUT UNITI Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of fiber and other wireless solutions for the communications industry. As of March 31, 2024, Uniti owns...

Continue reading

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2024, and provided an update on its corporate activities and product pipeline. “Our reacquisition of our CD388 program, which we have developed to date in collaboration with Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, (Janssen) as a once-per-flu season universal preventative of influenza A and B, along with the divestiture of the rezafungin program to our former partner Mundipharma, enables us to focus all of our development efforts...

Continue reading

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Fortress‘ late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025 FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, May 15, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2024. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said,...

Continue reading

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment Company received approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for “neldaleucel” as nonproprietary name for MT-601 HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today reported corporate updates and financial results for the first quarter ended...

Continue reading

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announced related positive top-line FORESEE clinical trial data Management to Host Conference Call May 15, 2024 at 5:00 p.m. ET AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights. Q1 2024 AND RECENT HIGHLIGHTS AND MILESTONE ACHIEVEMENTS...

Continue reading

Nova LifeStyle, Inc. Reports First Quarter FY 2024 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced financial results for the first quarter ended March 31, 2024. Tawny Lam, Chairperson and Chief Executive Officer of Nova LifeStyle, stated, “It is with great pleasure that we announce financial and operating results that showed increases in revenues, sales volume and higher gross profit margins. We continue to collaborate with our customers to ensure we provide furniture that meets their needs with respect to design, functionality and trends, while also working with manufacturers and suppliers on a consistent basis resulting in product availability and maintaining satisfactory inventory levels.” Key Financial Highlights: Net sales for the three months ended March 31, 2024 were $2.38 million, an increase...

Continue reading

Fluent Announces First Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Revenue of $66.0 million for Q1 2024 Net loss of $6.3 million for Q1 2024 Gross profit (exclusive of depreciation and amortization) of $18.6 million for Q1 2024 Media margin of $22.1 million for Q1 2024 Adjusted EBITDA of $0.7 million for Q1 2024 Adjusted net loss of $4.2 million for Q1 2024     NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading data-driven performance marketing company, today reported financial results for the first quarter ended March 31, 2024. Don Patrick, Fluent’s Chief Executive Officer, commented, “For the quarter, we reported improved gross margins over last year with positive adjusted EBITDA as we continued to deliver both leading and emerging brands a broader suite of customer acquisition and partner monetization solutions. Our new syndicated performance marketplaces...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.